The German co-operative study COALL-92 was designed to examine the clinical effectiveness of thioguanine (TG) versus mercaptopurine (MP) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL) in a randomized multicenter trial. TG and MP are prodrugs and have to be converted intracellularly to 6-thioguanine nucleotides (TGN) for cytostatic activity. TG is converted into TGN in fewer steps and has been shown to be more cytotoxic in equimolar doses in vitro compared to 6-MP. Therefore a higher effectiveness of TG in maintenance treatment was postulated.
INTRODUCTION
The prognosis of children with ALL has markedly improved during the past 30 years.
Nevertheless, still 25% of the children suffer a relapse. Current research mainly focuses on identification of further prognostic factors for better risk-adapted treatment strategies. On the other hand the use of other, not necessarily new drugs might improve outcome in childhood ALL. 
PATIENTS AND METHODS

Patients
From February 1992 until August 1997 561 children 1 to 18 years of age with B-precursor B-ALL or T-ALL were enrolled from the 19 participating German hospitals. A total of 41 patients (7,1%) were not eligible for COALL-92 according to the protocol criteria. Twentyfive of these patients had undergone major pre-treatment, 10 received inadequate treatment because of nonmedical reasons, in 4 biphenotypical leukemia was diagnosed and 2 patients died prior to any treatment. Thus, 521 patients were eligible for the study. Informed consent was obtained from all patients, respectively their parents. Diagnosis of ALL was established when at least 25% lymphoblasts were present in the bone marrow (BM) or when blasts were present in cerebrospinal fluid (CSF). BM, blood smears and CSF cytospin were reviewed centrally in the laboratory of the study in Hamburg, Germany. CNS involvement was diagnosed if more than 5 cells per µl were counted in the CSF with unequivocal lymphoblasts.
Immunophenotypic subgroups were defined according to the criteria provided by the European Group for the Immunological Characterization of Leukemias: common ALL:
terminal deoxynucleotide transferase (TdT) +, CD19+, CD10+, cytoplasmic (cy)IgM-, surface immunoglobulin (sIg) -; pre-B-ALL: : TdT +, CD19+, CD10± , cyIgM+, sIg-; pro-B-ALL:
TdT +, CD19+, CD10-, cyIgM-, sIg-; T-ALL: TdT+, cyCD3+, CD7+
6 . Surface antigens were considered positive if at least 20% of the leukemic cells expressed the antigen. Molecular screening for rearrangement of BCR/ABL, TEL/AML1 and MLL/AF4 was carried out in most patients.
Patient stratification and treatment
Patients were stratified into a LR or HR group according to age, initial white blood count (WBC) and immunological subtype. Patients in the LR group had a WBC of less than
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From 25000/µl, were aged 1 to 9 years and had common-or pre-B-ALL. HR patients had a WBC 25000/µl or were 10 years old or presented with pro-B-ALL or T-ALL. Furthermore, all patients with Philadelphia chromosome positive ALL (Phi+) and those patients who did not achieve complete remission until day 29 of the protocol were treated according to the HR protocol. Figure I shows an outline of the treatment strategy, the details of the protocol elements are provided in Table I . In contrast to the prior COALL protocol besides randomisation in maintenance treatment two further treatment modifications were evaluated: limitation of preventive cranial irradiation (CRT) to high risk (HR) patients with T-ALL or white blood count (WBC) 25000/µl in order to avoid toxicity and administration of a daunorubicin (DNR) prephase in order to examine the efficacy of prolonged less cardiotoxic anthracycline infusions with bolus treatment.
LR patients without primary CNS involvement received a total of 18 injections of intrathecal MTX in age-adjusted dosage (12 during intensive treatment and 6 during maintenance therapy). Preventive CNS irradiation at age-adjusted dosage (12-18 Gy) was given only to HR with T-ALL or WBC 25000/µl. During intensive phase HR patients received a total of 12 doses MTX intrathecally; to patients who did not undergo CRT the additional 6 additional injections during maintenance treatment were given.
During the study the following amendments were made in April 1994: -According to the policy of the previous studies to stepwise increase the leukocyte count above which preventive cranial irradiation (CRT) should be given patients with Bprecursor ALL and WBC < 50000/µl were excluded from CRT.
-DNR dose on day 22 was omitted to reduce the total anthracycline dose to that of the previous protocol.
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Allogenic bone marrow transplantation (BMT) was recommended for Phi+ ALL defined by translocation t(9;22) or BCR/ABL rearrangement, t(4;11) or late/nonresponse to induction therapy (Patients not in remission on day 29 continued the protocol and had another BM examination 2-4 weeks later. Those obtaining CR by day 56 were called lateresponders; if no remission was achieved by this time the patient was considered a nonresponder).
Randomization
After completion of intensive treatment patients were randomised within the low and high risk group to receive either MP or TG p.o. daily at a scheduled dose of 50 mg/m². When thrombocytopenia turned out to be a major problem starting dose of TG was reduced to 40 mg/m². In addition MTX was given orally at a scheduled dose of 20 mg/m². Doses were then adjusted in order to maintain the WBC between 2000-3000/µl. For all patients, the total duration of therapy was 24 months. WBC, percentage of lymphocytes and granulocytes, platelets, drug doses of MP, TG and MTX, reasons and duration of treatment interruptions were recorded for each patient weekly and evaluated centrally.
Statistical analysis
Duration of EFS in this study was defined as the time from start of maintenance treatment until the date of failure (death, relapse, second malignancy). In alteration of the usual definition of EFS induction failures such as death during induction therapy or failure to achieve complete remission by day 56 (nonresponse) did not find consideration in this For personal use only. on April 14, 2017. by guest www.bloodjournal.org From maintenance treatment. Probability of EFS was estimated as intent to treat by using the Kaplan-Meier method and log-rank tests were used to evaluate differences between the EFS in patient groups 7, 8 . Patients without failure were censored at the day of last follow-up on September 1, 2002.
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From (range 400 -125800/µl). B-cell-precursor ALL predominated (85%); only 15% of patients had T-ALL. Among patients with B-cell-precursor ALL, common ALL was diagnosed in 66,8%, pre-B-ALL in 15,7% and pro-B-ALL in 2,5%. The distribution of immunosubtypes was identical to that in former studies. Primary CNS involvement was diagnosed in 3,1% of all patients, 4 boys (1,3%) had testicular involvement. CRT was given to 165 HR patients (60%) and to 2 LR patients 0.8%). Among 407 patients successfully tested with cytogenetic or molecular genetic methods, 7 (1,7%) were positive to have Phi+ ALL.
RESULTS
Of 488 patients eligible for randomisation 474 patients respectively their guardians accepted randomisation: 238 children received MP, 236 children TG. Fourteen patients were allotted to the MP group according to choice of the parents. Table III gives the initial characteristics in both randomisation groups. Distribution regarding sex, age, initial WBC, immunological subtypes, risk groups was comparable in both arms. In the LR group 2 patients received CRT, both randomized to the TG arm. Of the HR patients 155 received CRT.
Further 33 patients were not randomised due to early death (2), nonresponse (5), early relapse (8), death in remission (5), bone marrow transplantation in 1.CCR due to Philadelphia chromosome (7) or lateresponse (5), lost to follow (1).
EFS was estimated as inte nt to treat analysis from the start of maintenance treatment. The probability of EFS for the MP group was 78% ± 3 and 78% ± 3 for the TG group (p value = 0.87) with a median observation time of 7.6 years ( Figure II) . Forty-seven relapses, mostly in bone marrow, occurred in the MP group, 45 relapses in the TG group. However, risk for CNS relapse was higher in patients receiving TG during maintenance treatment (p value = 0.053).
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In both randomisation arms these events occurred mainly in patients with high risk features.
According to risk groups EFS rate was 73% ± 5 (TG) versus 80% ± 4 (MP) for HR patients (p value = 0.73) and 84% ± 3 (TG) versus 77% ± 5 (MP) for the LR group (p value = 0.77) (Table IV) . While still on maintenance treatment in the MP group one patient died during remission due to cerebral infarction, two developed second malignancy (Morbus Hodgkin, osteosarcoma). The patient developing Morbus Hodgkin 8 years after T-ALL was diagnosed received preventive CRT during primary treatment, the other one had been treated according the LR protocol because of Pre-B-ALL 7.5 years earlier and did not receive CRT. In the TG group one patient died in complete remission due to viral encephalitis and pneumonia after maintenance treatment, in 3 children second malignancies had to be diagnosed (AML, glioblastoma, osteosarcoma). All these 3 patients initially presented with HR features and had preventive CRT because of T-ALL. It is of importance that AML had to be diagnosed only 10 months after start of ALL treatment Toxicity data of maintenance treatment were available in 257 patients. Toxicity profiles based on a total number of 17529 weeks of documented maintenance therapy forms differed markedly in the both treatment arms. During this time maintenance treatment had to be interrupted for 255 weeks (2.8%) in the MP group. In the TG group treatment interruptions occurred at a 1.7 fold higher rate. Therapy had to be stopped for the total amount of 389 weeks (4.7%). The higher frequency of interruptions was due to a 7.5 fold higher incidence of thrombocytopenia below 100000/µl without evidence of leukocytopenia below 1000/µl. In 70% of these episodes platelets dropped to values between 50000-100000/µl, in 8% below 25000/µl. Severe bleeding did not occur in any of these cases, however, in 10 occasions platelets transfusions were given. Other reasons for treatment interruptions like leukocytopenia or infections with or without leukocytopenia occurred at comparable rates in both groups.
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In spite of the higher rate of treatment interruptions the mean WBC was comparable in both groups (MP: 3400/µl; TG: 3600/µl). Also mean lymphocyte counts were analysed since lymphocytopenia might better reflect the cytotoxic effect on lymphoblasts. In both groups the mean value was 700/µl. Further analysis revealed that most episodes of 'isolated' thrombocytopenia were accompanied by prolonged lymphocytopenia but not necessarily low
WBC. An analysis of EFS according to mean lymphocyte count at several cut points (< vs > 500/µl; < vs > 1000/µl; < vs > 1500/µl) was made showing no statistical difference so far.
Mean drug doses were 25% lower in the TG group (MP: 49 mg/m²; TG: 36 mg/m²). On molar basis the mean thioguanine dose was even 30% lower (MP: 315 µmol/m²; TG: 215 µmol/m²).
A detailed analysis regarding hematologic toxicity will be published elsewhere. Analysis of EFS according to the amendments resulted in similar outcome as well.
The probability for EFS of all 521 patients was 74% ± 3 after a median observation time of 6,6 years (range 0 -8,6 years); the estimate of disease-free survival (DFS) was 77% ± 3 and the estimate of overall survival (OS) was 83% ± 2.
DISCUSSION
Trial COALL-92 was the largest of the 5 studies of the COALL study group so far. The combination chemotherapy corresponded to the former protocol. The EFS of 74% represents a constant result in comparison to the former trial COALL-89 9 . The incidence of CNS recurrences remained as low as it was in trials COALL-85 and -89 in spite of limitation of CRT to patients with T-ALL or patients with WBC 25000/µl ( 50000/µl) and Non-T-ALL.
Results of DNR response are reported elsewhere (submitted).
According to the studies of Lilleyman et al. 4 which showed an increased risk of relapse for children with low TGN levels during maintenance therapy with MP an improvement of EFS with TG was expected because of its differences in metabolism. Actually measurements of TGN concentrations in a subset of our patients confirmed that during TG treatment TGN levels exceeded 7 times those of the MP group 10 . Nevertheless in our study maintenance treatment with TG was not more effective than the standard therapy with MP and more complicated to handle due to a specific toxicity profile of prolonged myelosuppression with marked thrombocytopenia (submitted).
It could be argued that the frequent treatment interruptions in the TG group might have neutralized the possible superiority of TG. However, when effective treatment on leukemic cells is measured either by total leukocyte count, neutrophil count or maybe even more appropriately by lymphocyte count, the patients receiving TG had not less myelosuppression and even more prolonged lymphocytopenia.
Why then were the high TGN levels of no therapeutic advantage? One explanation could be that the impact of maintenance treatment and therefore also of changes in this part of therapy is less pronounced in a very intensive frontline protocol. 
Figure I
Simplified therapeutic scheme of Study COALL-92.
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Figure II
Probability of event-free-survival (EFS) for patients who were randomized to receive either mercaptopurine or thioguanine during maintenance treatment according to protocol COALL-92 . 
